Filing Flows › Angiodynamics (ANGO) › Q4 FY26 › vs Q3 FY26
Angiodynamics (ANGO) Q4 FY26 vs Q3 FY26 (quarter over quarter)
Angiodynamics's revenue rose $8.2M (+10%) from $78.4M in Q3 FY26 to $86.6M in Q4 FY26.
Angiodynamics, Q4 FY26: revenue $86.6M (+8% year over year), operating margin -11.8%, net loss $11.4M, operating cash flow $17.5M. The chart draws each line against Q3 FY26, the increases inside each band.
Margins
| Q4 FY26 | Q3 FY26 | Change | |
|---|---|---|---|
| Free cash flow margin | 19.7% | -5.3% | +24.9 pts |
Every line
| Line | Q4 FY26 | Q3 FY26 | Change | % |
|---|---|---|---|---|
| Revenue | $86.6M | $78.4M | $8.2M | +10% |
| Net loss | $11.4M | $8.1M | $3.3M | +41% |
| Costs & expenses | $98.0M | $91.4M | $6.6M | +7% |
| Operating costs | $96.8M | $91.4M | $5.4M | +6% |
| Interest & other, net | $840K | −$4.9M | $5.7M | — |
| Income tax | $370K | $12K | $358K | 31× |
| Cost of revenue | $39.8M | $36.9M | $2.9M | +8% |
| Research & development | $8.2M | $7.1M | $1.1M | +15% |
| Sales & marketing | $31.1M | $27.4M | $3.7M | +13% |
| General & admin | $10.3M | $10.7M | −$453K | -4% |
| Other operating costs | $7.4M | $9.2M | −$1.8M | -19% |
| Operating cash sources | $28.9M | $5.0M | $23.9M | +480% |
| Depreciation & amortization | $5.6M | $5.6M | $6K | +0.1% |
| Share-based compensation | $3.9M | $2.7M | $1.2M | +46% |
| Working capital & other | $19.3M | −$3.3M | $22.6M | — |
| Net loss absorbed | $11.4M | $8.1M | $3.3M | +41% |
| Operating cash flow | $17.5M | −$3.1M | $20.6M | — |
| Free cash flow (OCF − capex) | $17.0M | −$4.1M | $21.2M | — |
| Capital expenditures | $413K | $1.0M | −$602K | -59% |
Questions
How much did Angiodynamics's revenue grow quarter over quarter in Q4 FY26?
Angiodynamics's revenue rose $8.2M (+10%) from $78.4M in Q3 FY26 to $86.6M in Q4 FY26.